Debs Shaver-Vernon 🇨🇦

MOST PEOPLE THINK IVERMECTIN, FENBENDAZOLE & MEBENDAZOLE DO THE SAME THING. THEY DON'T. One of the questions people ask most is: "Why do some protocols include all three?" They're not. Because they aren't being studied for the same biological pathways. The infographic summarizes 12 biological mechanisms that researchers have investigated for each medicine in laboratory and preclinical studies. Here's why they're often discussed together: 💊 Ivermectin Researchers have studied its potential effects on: ✅ Cancer stem cells ✅ WNT/β catenin signaling ✅ mTOR signaling ✅ Tumor blood vessel formation ✅ Chemotherapy resistance 💊 Fenbendazole Research has explored its potential role in: ✅ Microtubule disruption ✅ Glucose metabolism ✅ p53 activation ✅ Metastasis ✅ AKT signaling 💊 Mebendazole Researchers have investigated it for: ✅ Crossing the blood brain barrier ✅ VEGF signaling ✅ Microtubule destabilization ✅ MYC expression ✅ Improving chemotherapy sensitivity That's why many researchers don't view these medicines as doing the exact same thing. They've been studied for different pathways, different targets, and different biological effects. Much of this research comes from laboratory and animal studies, and larger human clinical trials are still needed to determine whether these mechanisms translate into safe and effective cancer treatments. But understanding how they're being studied helps explain why all three continue to be part of the conversation. 💬 If different medicines target different biological pathways, do you think combination approaches deserve more clinical research than studying each medicine alone? Repost and like this post, and feel free to share your thoughts in the comments. Follow for more helpful updates and assistance.